Novavax Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Novavax (NVAX) Misses Q3 EPS by 3c
November 9, 2015 9:29 AM ESTNovavax (NASDAQ: NVAX) reported Q3 EPS of ($0.12), $0.03 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $6.53 million versus the consensus estimate of $10.59 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
... MoreNovavax (NVAX) Announces Initiation of RSV F Vaccine Phase 3 in Older Adults
November 9, 2015 6:56 AM ESTNovavax (NASDAQ: NVAX) announced the initiation of a Phase 3 clinical trial, known as Resolve, of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults (60 years of age and older).
The Resolve trial is a randomized, observer-blinded, placebo-controlled trial designed to enroll up to 11,850 older adults at 60 sites in the United States.... More
